Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8

Yan, W; Liu, S; Xu, E; Zhang, J; Zhang, Y; Chen, X; Chen, X

doi:10.1038/onc.2012.81

Cited by 156Histone Deacetylase Inhibitors ResearchCancer-related Molecular PathwaysGenomics and Chromatin Dynamics

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8

Open access

Yan, W, Liu, S, Xu, E, Zhang, J, Zhang, Y, Chen, X, Chen, X·2013·Oncogene

DOI 10.1038/onc.2012.81PMC PMC3371110

Open this paper in CoChat — free account

Abstract

Mutation of the p53 gene is the most common genetic alteration in human cancer and contributes to malignant process by enhancing transformed properties of cells and resistance to anticancer therapy. Mutant p53 is often highly expressed in tumor cells at least, in part, due to its increased half-life. However, whether mutant p53 expression is regulated by other mechanisms in tumors is unclear. Here we found that histone deacetylase (HDAC) inhibitors suppress both wild-type and mutant p53 transcription in time- and dose-dependent manners. Consistent with this, the levels of wild-type and mutant p53 proteins are decreased upon treatment with HDAC inhibitors. Importantly, we found that upon knockdown of each class I HDAC, only HDAC8 knockdown leads to decreased expression of wild-type and mutant p53 proteins and transcripts. Conversely, we found that ectopic expression of wild-type, but not mutant HDAC8, leads to increased transcription of p53. Furthermore, we found that knockdown of HDAC8 results in reduced expression of HoxA5 and consequently, attenuated ability of HoxA5 to activate p53 transcription, which can be rescued by ectopic expression of HoxA5. Because of the fact that HDAC8 is required for expression of both wild-type and mutant p53, we found that targeted disruption of HDAC8 expression remarkably triggers proliferative defect in cells with a mutant, but not wild-type, p53. Together, our data uncover a regulatory mechanism of mutant p53 transcription via HDAC8 and suggest that HDAC inhibitors and especially HDAC8-targeting agents might be explored as an adjuvant for tumors carrying a mutant p53.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/onc.2012.81

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

SAHA was recently found to also down regulate wild type p53, suggesting that it should be applied only to homozygous mut-p53 tumors.
“However, SAHA was recently found to also down regulate wt-p53 [147], suggesting that it should be applied only to homozygous mut-p53 tumors.”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [147]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase
Vaziri, H., Dessain, S. K., Eaton, E. N., Imai, S., Frye, R. A., Pandita, T. K., Guarente, L., & Weinberg, R. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00527-x · Cited by 2,653 · see citing works
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1779 · Cited by 2,211 · see citing works
Acetylation and deacetylation of non-histone proteins
Glozak, M. A., Sengupta, N., Zhang, X., & Seto, E. (2005) · Gene · doi:10.1016/j.gene.2005.09.010 · Cited by 1,584 · see citing works
Inhibition of Histone Deacetylase Activity by Butyrate
Davie, J. R. (2003) · The Journal of Nutrition · doi:10.1093/jn/133.7.2485s · Cited by 1,515 · see citing works
HDAC family: What are the cancer relevant targets?
Witt, O., Deubzer, H. E., Milde, T., & Oehme, I. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.08.016 · Cited by 1,069 · see citing works
Deacetylation of p53 modulates its effect on cell growth and apoptosis
Luo, J., Su, F., Chen, D., Shiloh, A., & Gu, W. J. (2000) · Nature · doi:10.1038/35042612 · Cited by 818 · see citing works
Histone deacetylase inhibitors: Potential in cancer therapy
Marks, P. A., & Xu, W. ‐. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22185 · Cited by 716 · see citing works
Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors
Khan, N., Jeffers, M., Kumar, S., Hackett, C., Boldog, F., Khramtsov, N., Qian, X., Mills, E., Berghs, S. C., Carey, N., et al. (2008) · Biochemical Journal · doi:10.1042/bj20070779 · Cited by 713 · see citing works
Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases
Somoza, J. R., Skene, R. J., Katz, B. A., Mol, C., Ho, J. D., Jennings, A. J., Luong, C., Arvai, A., Buggy, J. J., Chi, E., et al. (2004) · Structure · doi:10.1016/j.str.2004.04.012 · Cited by 710 · cited 1× · see citing works
“HDAC8 is a unique member of class I HDACs since it lacks the conserved C-terminal domain (12).”
Background
Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer
Wilson, A. J., Byun, D.-S., Popova, N., Murray, L. B., L'Italien, K., Sowa, Y., Arango, D., Velcich, A., Augenlicht, L. H., & Mariadason, J. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510023200 · Cited by 575 · see citing works
Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs.
(2011) · PubMed Central · Cited by 560 · see citing works
Histone deacetylase (HDAC) inhibitor activation of p21 WAF1 involves changes in promoter-associated proteins, including HDAC1
Gui, C., Ngo, L., Xu, W., Richon, V. M., & Marks, P. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307708100 · Cited by 550 · see citing works
Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors
Peart, M. J., Smyth, G. K., van Laar, R. K., Bowtell, D. D. L., Richon, V. M., Marks, P. A., Holloway, A. J., & Johnstone, R. W. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500369102 · Cited by 538 · see citing works
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications
Mitsiades, C. S., Mitsiades, N., McMullan, C. J., Poulaki, V., Shringarpure, R., Hideshima, T., Akiyama, M., Chauhan, D., Munshi, N. C., Gu, X., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2536759100 · Cited by 532 · see citing works
Untitled work
(2003) · PubMed · Cited by 519 · see citing works
Upregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate Cancer
Halkidou, K., Gaughan, L., Cook, S., Leung, H. Y., Neal, D. E., & Robson, C. N. (2004) · The Prostate · doi:10.1002/pros.20022 · Cited by 515 · see citing works
The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species
Ruefli, A. A., Ausserlechner, M. J., Bernhard, D., Sutton, V. R., Tainton, K. M., Kofler, R., Smyth, M. J., & Johnstone, R. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191208598 · Cited by 492 · see citing works
Compromised HOXA5 function can limit p53 expression in human breast tumours
Raman, V., Martensen, S. A., Reisman, D., Evron, E., Odenwald, W. F., Jaffee, E. M., Marks, J. R., & Sukumar, S. V. (2000) · Nature · doi:10.1038/35016125 · Cited by 482 · see citing works
A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas
Balasubramanian, S., Ramos, J., Luo, W., Sirisawad, M., Verner, E., & Buggy, J. J. (2008) · Leukemia · doi:10.1038/leu.2008.9 · Cited by 458 · see citing works
Isolation and Characterization of cDNAs Corresponding to an Additional Member of the Human Histone Deacetylase Gene Family
Yang, W., Yao, Y., Sun, J.-M., Davie, J., & Seto, E. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.44.28001 · Cited by 433 · see citing works
Histone Deacetylases Specifically Down-regulate p53-dependent Gene Activation
Juan, L.-J., Shia, W.-J., Chen, M.-H., Yang, W., Seto, E., Lin, Y.-S., & Wu, C.-W. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000202200 · Cited by 415 · see citing works
Histone deacetylase 8 in neuroblastoma tumorigenesis
Oehme, I., Deubzer, H. E., Wegener, D., Pickert, D., Linke, J.-P., Hero, B., Kopp-Schneider, A., Westermann, F., Ulrich, S. M., von Deimling, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0684 · Cited by 398 · see citing works
A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
Munster, P. N., Thurn, K. T., Thomas, S., Raha, P., Lacevic, M., Miller, A., Melisko, M., Ismail-Khan, R., Rugo, H., Moasser, M., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.156 · Cited by 391 · see citing works
Inside HDAC with HDAC inhibitors
Bertrand, P. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.02.030 · Cited by 363 · see citing works
The inherent instability of mutant p53 is alleviated by Mdm2 or p16 INK4a lossPreprint
Terzian, T., Suh, Y., Iwakuma, T., Post, S. M., Neumann, M., Lang, G. A., Pelt, C. S. V., & Lozano, G. (2008) · Genes & Development · doi:10.1101/gad.1662908 · Cited by 356 · see citing works
Increased expression of histone deacetylase 2 is found in human gastric cancer
SONG, J., Noh, J. H., LEE, J. H., Eun, J. W., Ahn, Y. M., Kim, S. Y., Lee, S. H., Park, W. S., Yoo, N. J., Lee, J. Y., et al. (2005) · Apmis · doi:10.1111/j.1600-0463.2005.apm_04.x · Cited by 347 · see citing works
Regulation of histone deacetylase activities
Sengupta, N., & Seto, E. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20179 · Cited by 347 · see citing works
Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma
Duvic, M., & Vu, J. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.7.1111 · Cited by 345 · see citing works
Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1
Huang, B., Laban, M., Leung, C. H.-W., Lee, L., Lee, C. K., Salto‐Tellez, M., Raju, G. C., & Hooi, S. C. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401567 · Cited by 337 · see citing works
SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis
Li, D., Marchenko, N. D., & Moll, U. M. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2011.71 · Cited by 336 · see citing works
Cloning and Characterization of a Novel Human Class I Histone Deacetylase That Functions as a Transcription Repressor
Hu, E., Chen, Z., Fredrickson, T., Zhu, Y., Kirkpatrick, R., Zhang, G.-F., Johanson, K., Sung, C.-M., Liu, R., & Winkler, J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m908988199 · Cited by 309 · see citing works
Histone deacetylases: transcriptional repression with SINers and NuRDs
Ayer, D. E. (1999) · Trends in Cell Biology · doi:10.1016/s0962-8924(99)01536-6 · Cited by 274 · see citing works
Cancer DNA Methylation: Molecular Mechanisms and Clinical Implications
McCabe, M. T., Brandes, J. C., & Vertino, P. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2784 · Cited by 265 · see citing works
SUMO-1 modification of histone deacetylase 1 (HDAC1) modulates its biological activities
David, G., Neptune, M. A., & DePinho, R. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203690200 · Cited by 236 · cited 1× · see citing works
“The C-terminal domain in HDAC1-3 is necessary for interacting with other proteins and for cellular localization (13) and posttranslational modifications (14, 15).”
Background
Novel mechanisms of apoptosis induced by histone deacetylase inhibitors.
Peart, M. J., Tainton, K. M., Ruefli, A. A., Dear, A. E., Sedelies, K. A., O’Reilly, L. A., Waterhouse, N. J., Trapani, J. A., & Johnstone, R. W. (2003) · PubMed · Cited by 231 · see citing works
Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
Kirschbaum, M. H., Frankel, P. H., Popplewell, L. L., Zain, J. M., Delioukina, M. L., Pullarkat, V. A., Matsuoka, D., Pulone, B., Rotter, A. J., Espinoza‐Delgado, I., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.1398 · Cited by 213 · see citing works
Structural Studies of Human Histone Deacetylase 8 and Its Site-Specific Variants Complexed with Substrate and Inhibitors<sup>,</sup>
Dowling, D. P., Gantt, S. L., Gattis, S. G., Fierke, C. A., & Christianson, D. W. (2008) · Biochemistry · doi:10.1021/bi801610c · Cited by 200 · see citing works
Regulation of histone deacetylase 2 by protein kinase CK2
Tsai, S.-C., & Seto, E. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204149200 · Cited by 196 · see citing works
Design and evaluation of ‘Linkerless’ hydroxamic acids as selective HDAC8 inhibitors
KrennHrubec, K., Marshall, B. L., Hedglin, M., Verdin, E. M., & Ulrich, S. M. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.02.064 · Cited by 195 · see citing works
Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies
Ramalingam, S. S., Parise, R. A., Ramananthan, R. K., Lagattuta, T. F., Musguire, L. A., Stoller, R. G., Potter, D. M., Argiris, A. E., Zwiebel, J. A., Egorin, M. J., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0162 · Cited by 193 · see citing works
Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells
Hrzenjak, A., Moinfar, F., Kremser, M., Strohmeier, B., Staber, P. B., Zatloukal, K., & Denk, H. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0480 · Cited by 163 · see citing works
Negative regulation of histone deacetylase 8 activity by cyclic AMP-dependent protein kinase A
Lee, H., Rezai-Zadeh, N., & Seto, E. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.2.765-773.2004 · Cited by 153 · see citing works
Histone Deacetylase 2 Modulates p53 Transcriptional Activities through Regulation of p53-DNA Binding Activity
Harms, K. L., & Chen, X. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4397 · Cited by 152 · see citing works
Self-citation
Histone acetylation-mediated regulation of genes in leukaemic cells
Chambers, A., Banerjee, S., Chaplin, T., Dunne, J., Debernardi, S., Joel, S. P., & Young, B. D. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00072-8 · Cited by 109 · see citing works
The C Terminus of p53 Family Proteins Is a Cell Fate Determinant
Harms, K. L., & Chen, X. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.5.2014-2030.2005 · Cited by 108 · see citing works
Self-citation
p73 or p53 Directly Regulates Human p53 Transcription to Maintain Cell Cycle Checkpoints
Wang, S., & El‐Deiry, W. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0511 · Cited by 108 · see citing works
The Activation Domains, the Proline-rich Domain, and the C-terminal Basic Domain in p53 Are Necessary for Acetylation of Histones on the Proximal p21 Promoter and Interaction with p300/CREB-binding Protein
Liu, G., Xia, T., & Chen, X. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210696200 · Cited by 107 · see citing works
Self-citation
Identification of GRO1 as a Critical Determinant for Mutant p53 Gain of Function
Yan, W., & Chen, X. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900994200 · Cited by 77 · see citing works
Self-citation
Transcriptional regulation of the p53 tumor suppressor gene
Reisman, D., & Loging, W. (1998) · Seminars in Cancer Biology · doi:10.1006/scbi.1998.0094 · Cited by 70 · see citing works
Inhibitors of histone deacetylases suppress cisplatin-induced p53 activation and apoptosis in renal tubular cells
Dong, G., Luo, J., Subbiah, V. K., & Dong, Z. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00410.2009 · Cited by 66 · see citing works
Marker genes to predict sensitivity to FK228, a histone deacetylase inhibitor
Sasakawa, Y., Naoe, Y., Sogo, N., Inoue, T., Sasakawa, T., Matsuo, M., Manda, T., & Mutoh, S. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.11.008 · Cited by 56 · see citing works
Identification of Transcriptional Targets of HOXA5
Chen, H., Rubin, E., Zhang, H., Chung, S., Jie, C. C., Garrett, E., Biswal, S. S., & Sukumar, S. V. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413528200 · Cited by 53 · see citing works
Identification of type-specific anticancer histone deacetylase inhibitors: road to success
Noureen, N., Rashid, H., & Kalsoom, S. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1324-y · Cited by 40 · see citing works
Characterization of Functional Domains Necessary for Mutant p53 Gain of Function
Yan, W., & Chen, X. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.097253 · Cited by 40 · see citing works
Self-citation

Flagged first, then by citations

Sorted by citations

p53 mutations in cancer
Muller, P. A. J., & Vousden, K. H. (2013) · Nature Cell Biology · doi:10.1038/ncb2641 · Cited by 1,647 · see citing works
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545 · see citing works
Targeting mutant p53 for cancer therapy: direct and indirect strategies
Hu, J., Cao, J., Topatana, W., Juengpanich, S., Li, S., Zhang, B., Shen, J., Cai, L., Cai, X., & Chen, M. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01169-0 · Cited by 557 · see citing works
The p53 Pathway in Glioblastoma
Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., et al. (2018) · Cancers · doi:10.3390/cancers10090297 · Cited by 440 · see citing works
Self-citation
Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy
Goh, G., Walradt, T. J., Markarov, V., Blom, A., Riaz, N., Doumani, R., Stafstrom, K., Moshiri, A. S., Yelistratova, L., Levinsohn, J. L., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6494 · Cited by 387 · see citing works
Metabolic functions of the tumor suppressor p53: Implications in normal physiology, metabolic disorders, and cancer
Lacroix, M., Riscal, R., Arena, G., Linares, L. K., & Cam, L. L. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.10.002 · Cited by 367 · see citing works
The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy
Guo, L., Tian, Y., & Zhu, W. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.576946 · Cited by 358 · see citing works
Targeting Oncogenic Mutant p53 for Cancer Therapy
Parrales, A., & Iwakuma, T. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00288 · Cited by 335 · see citing works
HDAC inhibitor‐based therapies: Can we interpret the code?
New, M. I., Olzscha, H., & Thangue, N. B. L. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.003 · Cited by 310 · see citing works
The rebel angel: mutant p53 as the driving oncogene in breast cancer
Walerych, D., Napoli, M., Collavin, L., & Sal, G. D. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs232 · Cited by 287 · see citing works
HDAC8: a multifaceted target for therapeutic interventions
Chakrabarti, A., Oehme, I., Witt, O., Oliveira, G., Sippl, W., Romier, C., Pierce, R. J., & Jung, M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.013 · Cited by 284 · see citing works
Mutant p53 in cancer therapy—the barrier or the path
Zhou, X. Y., Hao, Q., & Lu, H. (2018) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy072 · Cited by 244 · see citing works
Mutant p53 in Cancer Progression and Targeted Therapies
Zhu, G., Pan, C., Bei, J., Li, B., Chen, L., Xu, Y., & Fu, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.595187 · Cited by 222 · see citing works
Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer
Damaskos, C., Valsami, S. I., Kontos, M. C., Spartalis, E. D., Kalampokas, T., Kalampokas, E., Athanasiou, A., Moris, D., Daskalopoulou, A., Davakis, S., et al. (2017) · Anticancer Research · doi:10.21873/anticanres.11286 · Cited by 190 · see citing works
Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches
Alvarado-Ortiz, E., de la Cruz-López, K. G., Becerril-Rico, J., Sarabia-Sánchez, M. Á., Ortíz-Sánchez, E., & García-Carrancá, A. M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.607670 · Cited by 189 · see citing works
Targeting the DNA Damage Response in OSCC with TP 53 Mutations
Lindemann, A., Takahashi, H., Patel, A. A., Osman, A. A., & Myers, J. N. (2018) · Journal of Dental Research · doi:10.1177/0022034518759068 · Cited by 163 · see citing works
Histone Deacetylase HDAC8 Promotes Insulin Resistance and β-Catenin Activation in NAFLD-Associated Hepatocellular Carcinoma
Tian, Y., Wong, V. W., Wong, G. L., Yang, W., Sun, H., Shen, J., TONG, J. H. M., Go, M. Y. Y., Cheung, Y. S., Lai, P. B. S., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3786 · Cited by 134 · see citing works
Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials
Nishikawa, S., & Iwakuma, T. (2023) · Cancers · doi:10.3390/cancers15020429 · Cited by 115 · see citing works
Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview
Banerjee, S., Adhikari, N., Amin, S. A., & Jha, T. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.12.039 · Cited by 113 · see citing works
Targeting Histone Deacetylase 8 as a Therapeutic Approach to Cancer and Neurodegenerative Diseases
Chakrabarti, A., Melesina, J., Kolbinger, F. R., Oehme, I., Senger, J., Witt, O., Sippl, W., & Jung, M. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0117 · Cited by 111 · see citing works
The Histone Deacetylase Inhibitor, Vorinostat, Represses Hypoxia Inducible Factor 1 Alpha Expression through Translational Inhibition
Hutt, D. M., Roth, D. M., Vignaud, H., Cullin, C., & Bouchecareilh, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106224 · Cited by 109 · see citing works
HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer
Stojanovic, N., Hassan, Z., Wirth, M., Wenzel, P., Beyer, M., Schäfer, C., Brand, P., Kroemer, A., Stauber, R. H., Schmid, R. M., et al. (2016) · Oncogene · doi:10.1038/onc.2016.344 · Cited by 106 · see citing works
The Up-Regulation of Histone Deacetylase 8 Promotes Proliferation and Inhibits Apoptosis in Hepatocellular Carcinoma
Wu, J., Du, C., Lv, Z., Ding, C., Cheng, J., Xie, H., Zhou, L., & Zheng, S. (2013) · Digestive Diseases and Sciences · doi:10.1007/s10620-013-2867-7 · Cited by 103 · see citing works
Histone deacetylases function as novel potential therapeutic targets for cancer
Zhang, H., Shang, Y., Chen, H., & Li, J. (2016) · Hepatology Research · doi:10.1111/hepr.12757 · Cited by 99 · see citing works
NAT10 is upregulated in hepatocellular carcinoma and enhances mutant p53 activity
Li, Q., Liu, X., Jin, K., Lu, M., Zhang, C., Du, X., & Xing, B. (2017) · BMC Cancer · doi:10.1186/s12885-017-3570-4 · Cited by 98 · see citing works
Histone Deacetylases as New Therapeutic Targets in Triple-negative Breast Cancer: Progress and Promises
Garmpis, N., Damaskos, C., Garmpi, A., Kalampokas, E., Kalampokas, T., Spartalis, E. D., Daskalopoulou, A., Valsami, S. I., Kontos, M. C., Nonni, A., et al. (2017) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20041 · Cited by 96 · see citing works
Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine
Conway, J. R. W., Herrmann, D., Evans, T. J., Morton, J. P., & Timpson, P. (2018) · Gut · doi:10.1136/gutjnl-2018-316822 · Cited by 93 · see citing works
Hitting cancers’ weak spots: vulnerabilities imposed by p53 mutation
Gurpinar, E., & Vousden, K. H. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.04.001 · Cited by 94 · see citing works
Mutant p53: One, No One, and One Hundred Thousand
Walerych, D., Lisek, K., & Sal, G. D. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00289 · Cited by 92 · see citing works
p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death
Mrakovcic, M., Kleinheinz, J., & Fröhlich, L. F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102415 · Cited by 88 · see citing works
Histone deacetylase inhibitors suppress mutant p53 transcription via HDAC8/YY1 signals in triple negative breast cancer cells
Wang, Z., Chen, Z., Jiang, G., Wu, Y., Liu, T., Yi, Y., Zeng, J., Du, J., & Wang, H. (2016) · Cellular Signalling · doi:10.1016/j.cellsig.2016.02.006 · Cited by 87 · see citing works
Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms
Gao, S., Chen, C., Wang, L., Hong, L., Wu, J., Dong, P., & Yu, F. (2012) · Experimental Hematology · doi:10.1016/j.exphem.2012.10.012 · Cited by 86 · see citing works
HDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity
Karagiannis, D., & Rampias, T. N. (2021) · Cancers · doi:10.3390/cancers13143575 · Cited by 84 · see citing works
Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma
Singh, M. M., Johnson, B., Venkatarayan, A., Flores, E. R., Zhang, J., Su, X., Barton, M. C., Lang, F., & Chandra, J. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov041 · Cited by 83 · see citing works
Self-citation
Vorinostat suppresses hypoxia signaling by modulating nuclear translocation of hypoxia inducible factor 1 alpha
Zhang, C., Yang, C., Feldman, M. J., Wang, H., Pang, Y., Maggio, D. M., Zhu, D., Nesvick, C. L., Dmitriev, P., Bullova, P., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18125 · Cited by 80 · see citing works
Pathological Role of HDAC8: Cancer and Beyond
Kim, J. Y., Cho, H., Yoo, J. H., Kim, G. W., Jeon, Y. H., Lee, S. W., & Kwon, S. H. (2022) · Cells · doi:10.3390/cells11193161 · Cited by 79 · see citing works
Differential Mechanisms of Cell Death Induced by HDAC Inhibitor SAHA and MDM2 Inhibitor RG7388 in MCF-7 Cells
Natarajan, U., Venkatesan, T., Radhakrishnan, V., Samuel, S., & Rathinavelu, A. (2018) · Cells · doi:10.3390/cells8010008 · Cited by 75 · see citing works
Ginsenoside Rg3 Inhibits Constitutive Activation of NF-κB Signaling in Human Breast Cancer (MDA-MB-231) Cells: ERK and Akt as Potential Upstream Targets
Kim, B., Kim, D., Park, J.-H., Surh, Y., & Na, H. (2014) · Journal of Cancer Prevention · doi:10.15430/jcp.2014.19.1.23 · Cited by 75 · see citing works
Pure curcumin increases the expression of SOCS1 and SOCS3 in myeloproliferative neoplasms through suppressing class Ι histone deacetylases
Chen, C., Yu, K., Yan, Q., Xing, C., Chen, Y., Yan, Z., Shi, Y., Zhao, K.-W., & Gao, S. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt070 · Cited by 75 · see citing works
HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapy
Emmons, M. F., Faião-Flores, F., Sharma, R., Thapa, R., Messina, J. L., Becker, J. C., Schadendorf, D., Seto, E., Sondak, V. K., Koomen, J. M., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0040 · Cited by 73 · see citing works
Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations
Li, X., Wu, B. J., Chung, L. W. K., & Huang, W. (2015) · Oncotarget · doi:10.18632/oncotarget.5879 · Cited by 73 · see citing works
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation
Fu, S., Hou, M., Naing, A., Jankú, F., Hess, K. R., Zinner, R., Subbiah, V., Hong, D. S., Wheler, J. J., Piha-Paul, S. A., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv066 · Cited by 71 · see citing works
Is dual inhibition of metalloenzymes HDAC-8 and MMP-2 a potential pharmacological target to combat hematological malignancies?
Amin, S. A., Adhikari, N., & Jha, T. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.05.002 · Cited by 71 · see citing works
HDAC8 promotes the dissemination of breast cancer cells via AKT/GSK-3β/Snail signals
An, P., Chen, F., Li, Z., Ling, Y., Peng, Y., Zhang, H., Li, J., Chen, Z., & Wang, H. (2020) · Oncogene · doi:10.1038/s41388-020-1337-x · Cited by 67 · see citing works
Exome sequencing identifies a novelEP300frame shift mutation in a patient with features that overlap cornelia de lange syndrome
Woods, S. A., Robinson, H. B., Kohler, L. J., Agamanolis, D. P., Sterbenz, G., & Khalifa, M. (2013) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36237 · Cited by 66 · see citing works
HDAC8-dependent deacetylation of PKM2 directs nuclear localization and glycolysis to promote proliferation in hepatocellular carcinoma
Zhang, R., Shen, M., Wu, C., Chen, Y., Lu, J., Li, J., Zhao, L., Meng, H., Zhou, X., Huang, G., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03212-3 · Cited by 64 · see citing works
Ultra-Rare Syndromes: The Example of Rubinstein–Taybi Syndrome
Spena, S., Milani, D., & Gervasini, C. (2015) · Journal of Pediatric Genetics · doi:10.1055/s-0035-1564571 · Cited by 62 · see citing works
Targeting mutant p53: a key player in breast cancer pathogenesis and beyond
Qayoom, H., Haq, B. U., Sofi, S., Jan, N., Jan, A., & Mir, M. A. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01863-9 · Cited by 66 · see citing works
Histone deacetylases and atherosclerosis
Zheng, X., Zhou, T., Wang, X., Tong, X.-H., & Ding, J. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.12.048 · Cited by 56 · see citing works
Dysregulation of histone deacetylases in carcinogenesis and tumor progression: a possible link to apoptosis and autophagy
Patra, S., Panigrahi, D. P., Praharaj, P. P., Bhol, C. S., Mahapatra, K. K., Mishra, S. R., Behera, B. P., Jena, M., & Bhutia, S. K. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03098-1 · Cited by 58 · see citing works
Chromatinopathies: A focus on Cornelia de Lange syndrome
Avagliano, L., Parenti, I., Grazioli, P., Fede, E. D., Parodi, C., Mariani, M., Kaiser, F. J., Selicorni, A., Gervasini, C., & Massa, V. (2019) · Clinical Genetics · doi:10.1111/cge.13674 · Cited by 57 · see citing works
Histone Deacetylases (HDACs) as Mediators of Resistance to Apoptosis in Melanoma and as Targets for Combination Therapy with Selective BRAF Inhibitors
Lai, F., Jin, L., Gallagher, S. J., Mijatov, B., Zhang, X. D., & Hersey, P. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-397927-8.00002-6 · Cited by 55 · see citing works
HDACs and the epigenetic plasticity of cancer cells: target the complexity
Brancolini, C., Gagliano, T., & Minisini, M. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108190 · Cited by 55 · see citing works
Histone Deacetylase Inhibitor-Induced Autophagy in Tumor Cells: Implications for p53
Mrakovcic, M., Kleinheinz, J., & Fröhlich, L. F. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091883 · Cited by 53 · see citing works
Structure-Based Identification of HDAC8 Non-histone Substrates
Alam, N., Zimmerman, L., Wolfson, N. A., Joseph, C. G., Fierke, C. A., & Schueler‐Furman, O. (2016) · Structure · doi:10.1016/j.str.2016.02.002 · Cited by 51 · see citing works
Suberoylanilide hydroxamic acid (SAHA) promotes the epithelial mesenchymal transition of triple negative breast cancer cells via HDAC8/FOXA1 signals
Wu, S., Luo, Z., Yu, P. Y., Xie, H., & He, Y. (2015) · Biological Chemistry · doi:10.1515/hsz-2015-0215 · Cited by 53 · see citing works
Histone deacetylase inhibitors vorinostat and panobinostat induce G1 cell cycle arrest and apoptosis in multidrug resistant sarcoma cell lines
Bernhart, E. M., Stuendl, N., Kaltenegger, H., Windpassinger, C., Donohue, N., Leithner, A., & Lohberger, B. (2017) · Oncotarget · doi:10.18632/oncotarget.20460 · Cited by 52 · see citing works
Arsenic Trioxide Reactivates Proteasome-Dependent Degradation of Mutant p53 Protein in Cancer Cells in Part via Enhanced Expression of Pirh2 E3 Ligase
Yan, W., Jung, Y.-S., Zhang, Y., & Chen, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103497 · Cited by 51 · see citing works
Self-citation
Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53
Mrakovcic, M., Bohner, L. O. L., Hanisch, M. R., & Fröhlich, L. F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123952 · Cited by 48 · see citing works
Ribophorin II regulates breast tumor initiation and metastasis through the functional suppression of GSK3β
Takahashi, R., Takeshita, F., Honma, K., Ono, M., Kato, K., & Ochiya, T. (2013) · Scientific Reports · doi:10.1038/srep02474 · Cited by 47 · see citing works
Alterations in histone deacetylase 8 lead to cell migration and poor prognosis in breast cancer
Hsieh, C.-L., Ma, H.-P., Su, C.-M., Chang, Y.-J., Hung, W.-Y., Ho, Y.-S., Huang, W.-J., & Lin, R.-K. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.02.092 · Cited by 47 · see citing works
Discovery of pomalidomide-based PROTACs for selective degradation of histone deacetylase 8
Sun, Z., Deng, B., Yang, Z., Mai, R., Huang, J., Ma, Z., Chen, T., & Chen, J. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114544 · Cited by 46 · see citing works
Antitumor activity of vorinostat-incorporated nanoparticles against human cholangiocarcinoma cells
Kwak, T. W., Kim, D. H., Jeong, Y., & Kang, D. H. (2015) · Journal of Nanobiotechnology · doi:10.1186/s12951-015-0122-4 · Cited by 46 · see citing works
Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53
Terranova-Barberio, M., Pecori, B., Roca, M. S., Imbimbo, S., Bruzzese, F., Leone, A., Muto, P., Delrio, P., Avallone, A., Budillon, A., et al. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0647-5 · Cited by 48 · see citing works
A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors
Fontana, A., Cursaro, I., Carullo, G., Gemma, S., Butini, S., & Campiani, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710014 · Cited by 47 · see citing works
Class I histone deacetylases regulate p53/NF-κB crosstalk in cancer cells
Schäfer, C., Göder, A., Beyer, M., Kiweler, N., Mahendrarajah, N., Rauch, A., Nikolova, T., Stojanovic, N., Wieczorek, M., Reich, T. R., et al. (2016) · Cellular Signalling · doi:10.1016/j.cellsig.2016.11.002 · Cited by 46 · see citing works
Inhibition of urinary bladder cancer cell proliferation by silibinin
Barros, T. M. B., Lima, A. P. B., Almeida, T. C., & da Silva, G. N. (2020) · Environmental and Molecular Mutagenesis · doi:10.1002/em.22363 · Cited by 45 · see citing works
The regulation of radiosensitivity by p53 and its acetylation
Zhang, J., Shen, L., & Sun, L. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.04.015 · Cited by 45 · see citing works
Self-citation
Gain-of-function of mutant p53: mutant p53 enhances cancer progression by inhibiting KLF17 expression in invasive breast carcinoma cells
Ali, A., Shah, A. S., & Ahmad, A. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.07.045 · Cited by 43 · see citing works
NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme by Downregulating the β-Catenin/c-Myc/SOX2 Pathway and Upregulating p53-Mediated MGMT Inhibition
Tsai, C.-Y., Ko, H.-J., Chiou, S.-J., Lai, Y.-L., Hou, C.-C., Javaria, T., Huang, Z.-Y., Cheng, T.-S., Hsu, T., Chuang, J., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115907 · Cited by 43 · see citing works
Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status
Patyka, M., Sharifi, Z., Petrecca, K., Mansure, J., Jean-Claude, B., & Sabri, S. (2016) · Oncotarget · doi:10.18632/oncotarget.11197 · Cited by 42 · see citing works
The Contrived Mutant p53 Oncogene – Beyond Loss of Functions
Sabapathy, K. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00276 · Cited by 41 · see citing works
Structure–Activity Relationships of Hydroxamate-Based Histone Deacetylase-8 Inhibitors: Reality Behind Anticancer Drug Discovery
Amin, S. A., Adhikari, N., & Jha, T. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0130 · Cited by 41 · see citing works
Molecular Determinants of Cancer Therapy Resistance to HDAC Inhibitor-Induced Autophagy
Mrakovcic, M., & Fröhlich, L. F. (2019) · Cancers · doi:10.3390/cancers12010109 · Cited by 41 · see citing works
Plasticity of lung cancer stem-like cells is regulated by the transcription factor HOXA5 that is induced by oxidative stress
Saijo, H., Hirohashi, Y., Torigoe, T., Horibe, R., Takaya, A., Murai, A., Kubo, T., Kajiwara, T., Tanaka, T., Shionoya, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10571 · Cited by 40 · see citing works
Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors
Zhao, C., Zang, J., Ding, Q., Inks, E. S., Xu, W., Chou, C. J., & Zhang, Y. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.03.002 · Cited by 40 · see citing works
Self-citation
An appraisal of cinnamyl sulfonamide hydroxamate derivatives (HDAC inhibitors) for anti-cancer, anti-angiogenic and anti-metastatic activities in human cancer cells
Reddy, N. D., Shoja, M. H., Biswas, S., Nayak, P. G., Kumar, N., & Rao, C. M. (2016) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2016.05.008 · Cited by 39 · see citing works
SFRP1 is a possible candidate for epigenetic therapy in non-small cell lung cancer
Taguchi, Y., Iwadate, M., & Umeyama, H. (2016) · BMC Medical Genomics · doi:10.1186/s12920-016-0196-3 · Cited by 38 · see citing works
Gene Expression Profiling of Multiple Histone Deacetylases (HDAC) and Its Correlation with NRF2-Mediated Redox Regulation in the Pathogenesis of Diabetic Foot Ulcers
Rajan, T., Umapathy, D., Ali, D., Kesavan, R., & Ramkumar, K. M. (2020) · Biomolecules · doi:10.3390/biom10101466 · Cited by 37 · see citing works
Discovery of highly potent HDAC8 PROTACs with anti-tumor activity
Zhao, C., Chen, D., Suo, F., Setroikromo, R., Quax, W. J., & Dekker, F. J. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106546 · Cited by 40 · see citing works
HDAC8-mediated inhibition of EP300 drives a transcriptional state that increases melanoma brain metastasis
Emmons, M. F., Bennett, R. L., Riva, A., Gupta, K., Carvalho, L. A. D. C., Zhang, C., Macaulay, R. J. B., Dupéré-Richer, D., Fang, B., Seto, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43519-1 · Cited by 36 · see citing works
DEC1 Coordinates with HDAC8 to Differentially Regulate TAp73 and ΔNp73 Expression
Qian, Y., Zhang, J., Jung, Y.-S., & Chen, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0084015 · Cited by 36 · see citing works
Self-citation
Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk TP53 Mutation
Tanaka, N., Patel, A. A., Tang, L., Silver, N. L., Lindemann, A., Takahashi, H., Jaksik, R., Rao, X., Kalu, N. N., Chen, T., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0947 · Cited by 36 · see citing works
Novel histone deacetylase 8-selective inhibitor 1,3,4-oxadiazole-alanine hybrid induces apoptosis in breast cancer cells
Pidugu, V. R., Yarla, N. S., Bishayee, A., Kalle, A. M., & Satya, A. K. (2017) · APOPTOSIS · doi:10.1007/s10495-017-1410-2 · Cited by 36 · see citing works
TP53 Mutations in Esophageal Squamous Cell Carcinoma
Zhong, L., Li, H., Chang, W., Ao, Y., Wen, Z., & Chen, Y. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2809219 · Cited by 34 · see citing works
Neomorphic mutations create therapeutic challenges in cancer
Takiar, V., Ip, C. K. M., Gao, M., Mills, G. B., & Cheung, L. W. T. (2016) · Oncogene · doi:10.1038/onc.2016.312 · Cited by 31 · see citing works
Epigenetic Therapies in Ovarian Cancer Alter Repetitive Element Expression in a TP53 -Dependent Manner
McDonald, J. I., Diab, N., Arthofer, E., Hadley, M. M., Kanholm, T., Rentia, U., Gomez, S., Yu, A. Y. C., Grundy, E. E., Cox, O. L., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-4243 · Cited by 30 · see citing works
Modeling Cornelia de Lange syndrome in vitro and in vivo reveals a role for cohesin complex in neuronal survival and differentiation
Bottai, D., Spreafico, M., Pistocchi, A., Fazio, G., Adami, R., Grazioli, P., Canu, A., Bragato, C., Rigamonti, S., Parodi, C., et al. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy329 · Cited by 29 · see citing works
Targeting Histone Deacetylases 6 in Dual-Target Therapy of Cancer
Beljkaš, M., Ilić, A., Čebzan, A., Radović, B., Djoković, N., Ružić, D., Nikolic, K. M., & Oljačić, S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15112581 · Cited by 28 · see citing works
HDAC inhibitors show differential epigenetic regulation and cell survival strategies on p53 mutant colon cancer cells
Mahalakshmi, R., Pallikonda, H. A., & Mahadevan, V. (2017) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2017.1302820 · Cited by 26 · see citing works
Crosslink between p53 and metastasis: focus on epithelial–mesenchymal transition, cancer stem cell, angiogenesis, autophagy, and anoikis
Babaei, G., Aliarab, A., Vostakolaei, M. A., Hotelchi, M., Neisari, R., Aziz, S. G., & Bazl, M. R. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06706-1 · Cited by 26 · see citing works
Histone Deacetylases and Cancer-Associated Angiogenesis: Current Understanding of the Biology and Clinical Perspectives
CASTRONOVO, V., Peixoto, P., Bellahcène, A., & Turtoï, A. (2014) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2014012423 · Cited by 26 · see citing works
Mechanism of N-Acylthiourea-mediated Activation of Human Histone Deacetylase 8 (HDAC8) at Molecular and Cellular Levels
Singh, P., Cho, K., Padi, S. K. R., Yu, J., Haldar, M., Mandal, T., Yan, C., Cook, G. R., Guo, B., Mallik, S., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.600627 · Cited by 24 · see citing works
Targeting HDACs in Pancreatic Neuroendocrine Tumor Models
Schmitz, R. L., Weißbach, J., Kleilein, J., Bell, J. L., Hüttelmaier, S., Viol, F., Clauditz, T. S., Grabowski, P., Laumen, H., Rosendahl, J., et al. (2021) · Cells · doi:10.3390/cells10061408 · Cited by 23 · see citing works
Mutant p53 Sequestration of the MDM2 Acidic Domain Inhibits E3 Ligase Activity
Yang, L., Song, T., Cheng, Q., Chen, L., & Chen, J. (2018) · Molecular and Cellular Biology · doi:10.1128/mcb.00375-18 · Cited by 23 · see citing works
Examining the stability of binding modes of the co-crystallized inhibitors of human HDAC8 by molecular dynamics simulation
Uba, A. İ., Weako, J., Keskin, Ö., Gürsoy, A., & Yelekçi, K. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1615989 · Cited by 23 · see citing works
HDAC8 as a target in drug discovery: Function, structure and design
Zhao, Q., Liu, H., Peng, J., Niu, H., Liu, J., Xue, H., Liu, W., Liu, X., Hao, H., Zhang, X., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116972 · Cited by 23 · see citing works
Disarming mutant p53 oncogenic function
Girardini, J. E., Marotta, C., & Sal, G. D. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.003 · Cited by 22 · see citing works
Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies
Wang, Y., Jankú, F., Piha-Paul, S. A., Hess, K. R., Broaddus, R. R., Liu, L., Shi, N., Overman, M. J., Kopetz, S., Subbiah, V., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-58366-z · Cited by 22 · see citing works
Abnormal accumulation of p53 predicts radioresistance leading to poor survival in patients with endometrial carcinoma
Akiyama, A., Minaguchi, T., Fujieda, K., Hosokawa, Y., Nishida, K., Shikama, A., Tasaka, N., Sakurai, M., Ochi, H., & Satoh, T. (2019) · Oncology Letters · doi:10.3892/ol.2019.10940 · Cited by 21 · see citing works

Abstract 4517: HDAC inhibitors suppress p53 expression through transcriptional repression: Implication for therapy against metastatic breast cancer
Zhao, L., Li, Q., Seto, E., & Liao, D. (2010) · Cancer Research · doi:10.1158/1538-7445.am10-4517
HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer
Stojanovic, N., Hassan, Z., Wirth, M., Wenzel, P., Beyer, M., Schäfer, C., Brand, P., Kroemer, A., Stauber, R. H., Schmid, R. M., et al. (2016) · Oncogene · doi:10.1038/onc.2016.344 · Cited by 106 · see citing works
Histone Deacetylase 2 Modulates p53 Transcriptional Activities through Regulation of p53-DNA Binding Activity
Harms, K. L., & Chen, X. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4397 · Cited by 152 · see citing works
Self-citation
Depletion of Mutant p53 and Cytotoxicity of Histone Deacetylase Inhibitors
Blagosklonny, M. V., Trostel, S. Y., Kayastha, G., Demidenko, Z. N., Vassilev, L. T., Romanova, L. Y., Bates, S. E., & Fojo, T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3433 · Cited by 83 · see citing works
Histone deacetylase 5 is not a p53 target gene, but its overexpression inhibits tumor cell growth and induces apoptosis.
Huang, Y., Tan, M., Gosink, M. M., Wang, K., & Sun, Y. (2002) · PubMed · Cited by 45 · see citing works

Authors: Yan, W., Liu, S., Xu, E., Zhang, J., Zhang, Y., Chen, X., & Chen, X.
Affiliations: University of California, Davis (US)
Venue: Oncogene
Publisher: Springer Science and Business Media LLC
Published: 2012-03-05
Volume: 32
Issue: 5
Pages: 599-609
ISSN: 0950-9232 (ISSN-L)
1476-5594
DOI: 10.1038/onc.2012.81
PMC: PMC3371110
OpenAlex: W2030217455
Cited by: 153
References: 54
Citations by year: 2026: 7 · 2025: 4 · 2024: 3 · 2023: 8 · 2022: 9 · 2021: 10 · 2020: 16 · 2019: 13 · 2018: 11 · 2017: 16 · 2016: 15 · 2015: 17 · 2014: 10 · 2013: 9 · 2012: 5
FWCI: 5.27
Type: journal article
Language: en
Open access: green
europepmc.org
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Oncogene (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health
National Cancer Institute (R01CA076069, R01CA121137)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
Keywords: histone deacetylase inhibitors, mutant p53, HDAC8, HOXA5, class I HDACs, tumor suppressor regulation
MeSH terms: Vorinostat, Histone Deacetylases, Humans, Hydroxamic Acids, Mutation, Repressor Proteins, Transcription, Genetic, Genes, p53, Homeodomain Proteins, Cell Line, Tumor, Gene Knockdown Techniques, Histone Deacetylase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks